Justyl-AP Tablet is a combination medication containing Acebrophylline 100 mg and Acetylcysteine 600 mg, indicated primarily for the management of respiratory conditions characterized by bronchial obstruction and excessive mucus production. Acebrophylline acts as a bronchodilator with mucosecretolytic and anti-inflammatory properties, facilitating the relaxation of bronchial smooth muscles and improving airflow in obstructive airway diseases such as chronic bronchitis, asthma, and chronic obstructive pulmonary disease (COPD). Acetylcysteine serves as a mucolytic agent, breaking down disulfide bonds in mucus glycoproteins, thereby reducing mucus viscosity and promoting easier expectoration. The synergistic effect of these two active ingredients aids in alleviating symptoms such as cough, breathlessness, and chest congestion by enhancing mucociliary clearance and reducing airway inflammation. Justyl-AP is typically administered orally and should be used under medical supervision, especially in patients with known hypersensitivity to its components, peptic ulcer disease, or severe hepatic or renal impairment. Common adverse effects may include gastrointestinal disturbances, headache, or allergic reactions. This combination therapy offers an effective approach to improving respiratory function and patient quality of life in obstructive pulmonary disorders.